# Can Ozempic cause vision loss? · PepVault guides

Source: https://pepvault.app/guides/glp-1-and-naion

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers

Reviewed November 2026 28 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Ozempic, Wegovy and NAION: what the labels say as of November 2026, every large study with its absolute risk, the trial data, and what tirzepatide shows.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 28
- **Questions:** 9
- **Compounds:** 2

## The short answer

Semaglutide, the drug in Ozempic and Wegovy, is linked to NAION, a sudden loss of blood flow to the optic nerve, but the risk is small. Europe's regulator lists it as a very rare side effect: about one extra case per 10,000 people treated for a year. The large studies find roughly double a low starting risk; the randomised trials found no clear rise.

Every number checked at its primary source · Nov 20, 2026 · [28 sources](https://pepvault.app/guides/glp-1-and-naion#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Observational studies of several million people, mostly with type 2 diabetes, plus pooled randomised trials with few cases; Europe lists NAION as a very rare side effect of semaglutide, and no study proves the drug causes it.

## What is NAION?

NAION, short for non-arteritic anterior ischemic optic neuropathy, is a small stroke of the optic nerve, the cable that carries sight from the eye to the brain. The blood flow to the front of the nerve, where it leaves the eye, drops for a while, and the nerve fibres there are damaged. It usually shows up as sudden, painless loss of vision in one eye, often noticed on waking[24](https://pepvault.app/guides/glp-1-and-naion#source-24). The most common pattern is a missing upper or lower half of the view in that eye[25](https://pepvault.app/guides/glp-1-and-naion#source-25).

It was a known condition long before GLP-1 drugs. A Mayo Clinic count in one Minnesota county, 1990 to 2016, found about 4 new cases per 100,000 people a year, and about 10 per 100,000 among people aged 50 or older; the median age at diagnosis was 65[28](https://pepvault.app/guides/glp-1-and-naion#source-28). The known risk factors are high blood pressure, diabetes, blood pressure that falls low at night, and a small, crowded optic disc, the spot where the nerve enters the eye[24](https://pepvault.app/guides/glp-1-and-naion#source-24). There is no proven treatment for it[24](https://pepvault.app/guides/glp-1-and-naion#source-24).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's side-effect log keeps any symptom you type with its date, a severity from minimal to very severe and your notes, beside the compound, so you can show the eye doctor when a change began.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Does Ozempic cause NAION, according to the regulators?

Europe says yes, as a very rare side effect. On June 6, 2025, the European Medicines Agency's safety committee concluded that NAION is a side effect of semaglutide (Ozempic, Rybelsus and Wegovy) with a frequency of "very rare", up to 1 in 10,000 people. Large population studies in adults with type 2 diabetes showed about twice the risk, about one additional case per 10,000 person-years (one person on the drug for one year), and trials pointed to a slightly higher risk than placebo[17](https://pepvault.app/guides/glp-1-and-naion#source-17).

The European product information now says there is no known time window for when NAION may develop after starting, that sudden vision loss should lead to an eye examination, and that semaglutide is stopped if NAION is confirmed[18](https://pepvault.app/guides/glp-1-and-naion#source-18).

The US labels do not list it. As of November 2026, the FDA labels for Ozempic (DailyMed version 20, published June 10, 2026), Wegovy (version 19, June 30, 2026), Mounjaro and Zepbound (both version 40, September 2, 2026) carry no NAION or optic nerve warning; their eye warning is about diabetic retinopathy[19](https://pepvault.app/guides/glp-1-and-naion#source-19) [20](https://pepvault.app/guides/glp-1-and-naion#source-20) [21](https://pepvault.app/guides/glp-1-and-naion#source-21) [22](https://pepvault.app/guides/glp-1-and-naion#source-22).

In 2026 the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology wrote that many studies report a small possible increase, some find none, the overall risk stays low, and starting, continuing or stopping is a shared decision between patient and care team[16](https://pepvault.app/guides/glp-1-and-naion#source-16).

## How big is the NAION risk on a GLP-1, in real numbers?

Small in absolute terms. An observational study follows people in ordinary care, so the groups can differ in ways researchers cannot fully adjust for; a hazard ratio (HR) or risk ratio (RR) of 2 means about twice the rate.

| Study | Who | On the drug | Comparison group | Relative risk |
| --- | --- | --- | --- | --- |
| Hathaway 2024, US[1](https://pepvault.app/guides/glp-1-and-naion#source-1) | One specialist eye clinic, type 2 diabetes: 194 vs 516 | 8.9% over 3 years | 1.8% | HR 4.28 |
| Hathaway 2024, same clinic[1](https://pepvault.app/guides/glp-1-and-naion#source-1) | Overweight or obesity: 361 vs 618 | 6.7% over 3 years | 0.8% | HR 7.64 |
| Grauslund 2024, Denmark[2](https://pepvault.app/guides/glp-1-and-naion#source-2) | 424,152 with type 2 diabetes | 2.3 per 10,000 a year | 0.9 per 10,000 a year | HR 2.19 |
| Simonsen 2025, Denmark and Norway[3](https://pepvault.app/guides/glp-1-and-naion#source-3) | 61,377 on semaglutide vs SGLT-2 inhibitors | 2.2 and 2.9 per 10,000 a year | 1.2 and 0.9 | HR 2.81 |
| Cai 2025, 14 US databases[4](https://pepvault.app/guides/glp-1-and-naion#source-4) | 810,390 new semaglutide users | 1.5 per 10,000 a year | No significant difference vs three diabetes drugs (broad definition) | HR 1.23 to 1.44 |
| Wang 2025, US[7](https://pepvault.app/guides/glp-1-and-naion#source-7) | 79,699 on semaglutide or tirzepatide vs 79,699 | 0.04% over 2 years | 0.02% | HR 1.76 |
| Heberer 2026, US veterans[8](https://pepvault.app/guides/glp-1-and-naion#source-8) | 11,478 vs 90,883 on SGLT-2 inhibitors | 12.3 per 10,000 a year | 6.7 per 10,000 a year | HR 2.33 |
| Noh 2026, UK[9](https://pepvault.app/guides/glp-1-and-naion#source-9) | 106,858 starting any GLP-1 drug vs 416,369 on DPP-4 inhibitors | 1.9 per 10,000 in year one | 0.7 | RR 2.56 |
| Ueda 2026, Sweden[10](https://pepvault.app/guides/glp-1-and-naion#source-10) | 107,518 vs 185,898 on SGLT-2 inhibitors | 0.12% over 5 years | 0.07% | RR 1.69, not significant |
| Reynolds 2026, US, ages 18 to 65[11](https://pepvault.app/guides/glp-1-and-naion#source-11) | New users vs SGLT-2 or DPP-4 inhibitors | 8.5 and 7.8 per 10,000 over 18 months | 5.5 and 4.2 | 3.0 and 3.6 more per 10,000 (absolute) |

The Mass Eye and Ear study started the headlines, and its percentages are far higher because every patient had already been sent to a specialist eye clinic; it counted 17 cases against 6 in diabetes and 20 against 3 in the weight group[1](https://pepvault.app/guides/glp-1-and-naion#source-1). By our subtraction from the table, the drug adds about one to six cases per 10,000 people a year in the large studies. Reynolds put it as a number needed to harm: about 3,333 people treated for 18 months for one extra case, compared with an SGLT-2 inhibitor[11](https://pepvault.app/guides/glp-1-and-naion#source-11).

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Indication](https://pepvault.app/glossary/indication)
- [Observational study](https://pepvault.app/glossary/observational-study)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

## What did the randomised trials find?

Very few cases, and no clear rise. A randomised trial assigns the drug or a placebo by chance, which removes most of the differences that cloud the record studies, but NAION is so rare that even big trials see only a handful.

- **All Novo Nordisk placebo-controlled trials of semaglutide and liraglutide, pooled:** 96,829 people; three confirmed cases on a GLP-1 drug (about 3 per 100,000 person-years) and five in four people on placebo (about 6 per 100,000). Three of the six authors work for Novo Nordisk[12](https://pepvault.app/guides/glp-1-and-naion#source-12).
- **78 semaglutide trials** (73,640 people): an odds ratio of 3.92 for NAION, with a range so wide (1.02 to 15.02) that the authors called the evidence insufficient[13](https://pepvault.app/guides/glp-1-and-naion#source-13).
- **A 2026 meta-analysis by indication:** 5 cases against 1 in diabetes trials and 4 against 1 in weight-loss trials, neither a significant rise[14](https://pepvault.app/guides/glp-1-and-naion#source-14).

Pooling the record studies gives about two and a half times the risk (1.6 million people, RR 2.52) in one 2026 analysis[15](https://pepvault.app/guides/glp-1-and-naion#source-15), and no consistent increase, at low to very low certainty, in another[26](https://pepvault.app/guides/glp-1-and-naion#source-26).

## Why do the NAION studies disagree?

Mostly because people who get semaglutide differ from those who get the comparison drug. Diabetes itself raises NAION risk, and people prescribed a GLP-1 drug often have harder-to-control diabetes. In Sweden the 5-year risk ratio fell from 1.69 to 1.23 when the analysis kept only people already on metformin, a way to compare people at a similar stage, and the authors judged the rise may reflect that difference[10](https://pepvault.app/guides/glp-1-and-naion#source-10).

- **The comparison drug matters.** Against empagliflozin, sitagliptin or glipizide, the 14-database study found no significant difference by its broad definition[4](https://pepvault.app/guides/glp-1-and-naion#source-4).
- **Codes are blunt.** Some records have no specific NAION code, so studies count all ischemic optic neuropathy instead[11](https://pepvault.app/guides/glp-1-and-naion#source-11).
- **The timing does not line up.** The UK excess came mostly in the first 6 months[9](https://pepvault.app/guides/glp-1-and-naion#source-9), another study saw none in year one and a rise from year two[6](https://pepvault.app/guides/glp-1-and-naion#source-6), and in Denmark the median time to NAION was 22 months[2](https://pepvault.app/guides/glp-1-and-naion#source-2).

How semaglutide would cause it is not known. One clue: in the UK the excess was larger in people whose HbA1c, the three-month blood sugar average, fell by 1 point or more[9](https://pepvault.app/guides/glp-1-and-naion#source-9).

## Is NAION a risk on Wegovy for weight loss, or on Mounjaro and Zepbound?

For weight loss, the signal is weaker than in diabetes. Outside the single specialist clinic[1](https://pepvault.app/guides/glp-1-and-naion#source-1), the multinational study found no rise in people with obesity alone[5](https://pepvault.app/guides/glp-1-and-naion#source-5), and the 2026 meta-analysis found no significant rise in the weight-loss record studies (hazard ratio 1.57, range 0.69 to 3.59) or trials[14](https://pepvault.app/guides/glp-1-and-naion#source-14). The European review's numbers come from adults with type 2 diabetes[17](https://pepvault.app/guides/glp-1-and-naion#source-17).

For tirzepatide, the data are thin. The one large study that included it pooled it with semaglutide: 0.04% against 0.02% over two years in type 2 diabetes[7](https://pepvault.app/guides/glp-1-and-naion#source-7). Neither the US Mounjaro and Zepbound labels[21](https://pepvault.app/guides/glp-1-and-naion#source-21) [22](https://pepvault.app/guides/glp-1-and-naion#source-22) nor the European Mounjaro label[27](https://pepvault.app/guides/glp-1-and-naion#source-27) lists NAION; tirzepatide has simply been studied less.

## Who has a higher risk of NAION on a GLP-1?

Men and people over 50, in a US analysis of insured adults aged 18 to 65: the extra risk was largest in men, people over 50 and those with heart disease or an earlier eye condition, and minimal in women and under 50[11](https://pepvault.app/guides/glp-1-and-naion#source-11). The UK study also found it higher in men and smokers, but, unlike the US one, in people under 50 too[9](https://pepvault.app/guides/glp-1-and-naion#source-9).

## Is diabetic retinopathy the same risk as NAION?

No, it is a separate one, and it is the eye warning that sits on every US label. Diabetic retinopathy is damage to the small blood vessels of the retina, the light-sensing layer at the back of the eye, from years of high blood sugar. When blood sugar falls quickly, existing retinopathy can get worse for a while[19](https://pepvault.app/guides/glp-1-and-naion#source-19) [21](https://pepvault.app/guides/glp-1-and-naion#source-21).

| Trial or label | Who | On the drug | On placebo |
| --- | --- | --- | --- |
| SUSTAIN-6, 2 years[23](https://pepvault.app/guides/glp-1-and-naion#source-23) [19](https://pepvault.app/guides/glp-1-and-naion#source-19) | 3,297 adults with type 2 diabetes and high heart risk | 3.0% had retinopathy complications | 1.8% |
| SUSTAIN-6, with retinopathy at the start[19](https://pepvault.app/guides/glp-1-and-naion#source-19) | Same trial | 8.2% | 5.2% |
| SUSTAIN-6, no known retinopathy[19](https://pepvault.app/guides/glp-1-and-naion#source-19) | Same trial | 0.7% | 0.4% |
| Wegovy weight trial in type 2 diabetes[20](https://pepvault.app/guides/glp-1-and-naion#source-20) | Adults with type 2 diabetes and a BMI of 27 or more | 4% reported retinopathy | 2.7% |

Complications in SUSTAIN-6 meant bleeding inside the eye, blindness, or a need for laser or injection treatment[23](https://pepvault.app/guides/glp-1-and-naion#source-23). The Mounjaro and Zepbound labels carry a retinopathy warning too, and every label asks that people with retinopathy be monitored[19](https://pepvault.app/guides/glp-1-and-naion#source-19) [20](https://pepvault.app/guides/glp-1-and-naion#source-20) [21](https://pepvault.app/guides/glp-1-and-naion#source-21) [22](https://pepvault.app/guides/glp-1-and-naion#source-22).

## What should you do about your eyes on a GLP-1?

Know your starting point, and act quickly on a sudden change[18](https://pepvault.app/guides/glp-1-and-naion#source-18) [19](https://pepvault.app/guides/glp-1-and-naion#source-19) [20](https://pepvault.app/guides/glp-1-and-naion#source-20):

1. Before you start, tell your prescriber about any past NAION or optic nerve problem in either eye, and any diabetic eye disease.
2. If you have diabetic retinopathy, keep your regular eye checks through the dose climb; the labels ask for monitoring.
3. If your sight changes, cover one eye at a time to learn which eye it is, and note what is missing (a half, a patch, a blur) and when you noticed it.
4. At the visit, name the medicine, your dose and the date you started.

**When to get help** A sudden loss of vision, a dark or grey patch, or eyesight that gets worse over hours or days is a reason to be seen by an eye doctor or an emergency service the same day[17](https://pepvault.app/guides/glp-1-and-naion#source-17) [18](https://pepvault.app/guides/glp-1-and-naion#source-18).

<!--promo-->

PepVault's side-effect log keeps any symptom you type with its date, a severity from minimal to very severe and your notes, beside the compound, so you can show the eye doctor when a change began. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-glp-1-and-naion-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Hathaway JT et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. [PubMed 38958939](https://pubmed.ncbi.nlm.nih.gov/38958939/)
2. Grauslund J et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97. [PubMed 39696569](https://pubmed.ncbi.nlm.nih.gov/39696569/)
3. Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103. [PubMed 40098249](https://pubmed.ncbi.nlm.nih.gov/40098249/)
4. Cai CX et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4):304-314. [PubMed 39976940](https://pubmed.ncbi.nlm.nih.gov/39976940/)
5. Chou CC et al. Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study. Ophthalmology. 2025;132(4):381-388. [PubMed 39491755](https://pubmed.ncbi.nlm.nih.gov/39491755/)
6. Hsu AY et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes. JAMA Ophthalmol. 2025;143(5):400-407. [PubMed 40146102](https://pubmed.ncbi.nlm.nih.gov/40146102/)
7. Wang L et al. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327. [PubMed 40788646](https://pubmed.ncbi.nlm.nih.gov/40788646/)
8. Heberer K et al. New-onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in US veterans with type 2 diabetes. JAMA Ophthalmol. 2026;144(3):259-264. [PubMed 41678180](https://pubmed.ncbi.nlm.nih.gov/41678180/)
9. Noh Y et al. Glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes. Diabetes Care. 2026;49(5):763-771. [PubMed 41701611](https://pubmed.ncbi.nlm.nih.gov/41701611/)
10. Ueda P et al. Glucagon-like peptide-1 receptor agonists and risk for anterior ischemic optic neuropathy: a nationwide cohort study. Ann Intern Med. 2026;179(9):1232-1243. [PubMed 42441962](https://pubmed.ncbi.nlm.nih.gov/42441962/)
11. Reynolds KR et al. Glucagon-like peptide-1 receptor agonists and risk for ischemic optic neuropathy: a target trial emulation. Ann Intern Med. 2026;179(9):1244-1253. [PubMed 42441967](https://pubmed.ncbi.nlm.nih.gov/42441967/)
12. Vilsbøll T et al. Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide. Br J Ophthalmol. 2026. [PubMed 42049287](https://pubmed.ncbi.nlm.nih.gov/42049287/)
13. Natividade GR et al. Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol. 2025;143(9):759-768. [PubMed 40810985](https://pubmed.ncbi.nlm.nih.gov/40810985/)
14. Liu Z et al. Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133(5):589-598. [PubMed 41475544](https://pubmed.ncbi.nlm.nih.gov/41475544/)
15. Dhivagaran T et al. Glucagon-like peptide-1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy: systematic review and meta-analysis. Neurology. 2026;106(10):e214864. [PubMed 42060879](https://pubmed.ncbi.nlm.nih.gov/42060879/)
16. DeParis SW et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8):1029-1035. [PubMed 42132708](https://pubmed.ncbi.nlm.nih.gov/42132708/)
17. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. Published June 6, 2025. [ema.europa.eu](https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy)
18. European Medicines Agency. Ozempic: EPAR product information (sections 4.4 and 4.8), read November 20, 2026. [ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf)
19. OZEMPIC (semaglutide) injection, US prescribing information. DailyMed, set ID adec4fd2-6858-4c99-91d4-531f5f2a2d79, version 20, updated June 1, 2026, published June 10, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
20. WEGOVY (semaglutide) injection and tablets, US prescribing information. DailyMed, set ID ee06186f-2aa3-4990-a760-757579d8f77b, version 19, updated June 18, 2026, published June 30, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
21. MOUNJARO (tirzepatide) injection, US prescribing information. DailyMed, set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version 40, updated August 27, 2026, published September 2, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
22. ZEPBOUND (tirzepatide) injection, US prescribing information. DailyMed, set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, updated August 28, 2026, published September 2, 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
23. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. [PubMed 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)
24. Desai N et al. Nonarteritic anterior ischemic optic neuropathy. J Clin Hypertens (Greenwich). 2005;7(2):130-133. [PubMed 15722660](https://pubmed.ncbi.nlm.nih.gov/15722660/)
25. Hattenhauer MG et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(1):103-107. [PubMed 9186104](https://pubmed.ncbi.nlm.nih.gov/9186104/)
26. Abdelaal A et al. Semaglutide and the risk of nonarteritic ischemic optic neuropathy: a systematic review and certainty of evidence meta-analysis. Ophthalmology. 2026;133(6):799-810. [PubMed 41692115](https://pubmed.ncbi.nlm.nih.gov/41692115/)
27. European Medicines Agency. Mounjaro: EPAR product information (sections 4.4 and 4.8), read November 20, 2026. [ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf)
28. Foster RC et al. Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester Epidemiology Project study. J Neuroophthalmol. 2024;44(3):337-341. [PubMed 38358828](https://pubmed.ncbi.nlm.nih.gov/38358828/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)

The longest GLP-1 trials ran 2 to 5.4 years, and heart events and deaths were the same or lower on the drug. The long-term risks, the thyroid warning, cycling.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)

  Ozempic and Wegovy side effects from the labels' trials, drug against placebo: nausea and the rest, when they start, how many days they last, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)

  Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)

  Semaglutide vs tirzepatide side effects in the same trials: nausea, vomiting, reflux, hair loss and injection-site rates side by side, and how many stopped.

  Read the guide
- Guide · GLP-1s

  ### [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)

  What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Indication](https://pepvault.app/glossary/indication)
- [Observational study](https://pepvault.app/glossary/observational-study)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)
- [Body mass index (BMI)](https://pepvault.app/glossary/bmi)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
